- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) nonsmall cell lung cancer (NSCLC)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Alectinib and crizotinib – November 2019
Alectinib: Capsule 150 mg; Alecensa®; Crizotinib: Capsule 200 mg; Capsule 250 mg; Xalkori®
Last updated
9 July 2025